产品货号

CP006

反应种属

Mouse

同种型

Mouse IgG1(switched from mouse IgG2b)

实验应用

in vivo CTLA-4 neutralization*

Western blot*

*Reported for the original mouse IgG2b 9D9 antibody

纯度

>95%, Determined by SDS-PAGE

无菌处理

0.2 µm filtration

分子量

150 kDa

保存条件

抗体原液保存在4°C，不能冷冻保存。

推荐抗体稀释液

InVivoPure pH 7.0 Dilution Buffer（货号IP0070）

体内CTLA-4中和

(in vivo CTLA-4 

neutralization)

1. Dai, M., et al. (2015). 'Curing mice with large tumors by locally delivering 

combinations of immunomodulatory antibodies' Clin Cancer Res 21(5): 1127-1138.

2. Zippelius, A., et al. (2015). 'Induced PD-L1 expression mediates acquired 

resistance to agonistic anti-CD40 treatment' Cancer Immunol Res 3(3): 236-244.

3. Redmond, W. L., et al. (2014). 'Combined targeting of costimulatory (OX40) 

and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of 

driving robust antitumor immunity' Cancer Immunol Res 2(2): 142-153.

4. Condamine, T., et al. (2014). 'ER stress regulates myeloid-derived suppressor 

cell fate through TRAIL-R-mediated apoptosis' J Clin Invest 124(6): 2626-2639.

5. Muller, P., et al. (2014). 'Microtubule-depolymerizing agents used in antibody-drug 

conjugates induce antitumor immunity by stimulation of dendritic cells' Cancer Immunol 

Res 2(8): 741-755.

6. Bulliard, Y., et al. (2013). 'Activating Fc gamma receptors contribute to the antitumor 

activities of immunoregulatory receptor-targeting antibodies' J Exp Med 210(9): 1685-1693.